G01N 2333/4706
Stimulating, promoting or activating activity
Official title: stimulating, promoting or activating activity
G01N2333/4706 (Stimulating, promoting or activating activity) appears on 139 US grants and 277 published applications in this corpus.
Search patents in G01N- Granted patents
- 139
- Published applications
- 277
- Assignees
- 214
- Inventors
- 590
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 2 |
| 2003 | 1 | 6 |
| 2004 | 3 | 6 |
| 2005 | 1 | 3 |
| 2006 | 1 | 4 |
| 2007 | 3 | 3 |
| 2008 | 3 | 7 |
| 2009 | 2 | 10 |
| 2010 | 1 | 10 |
| 2011 | 6 | 17 |
| 2012 | 3 | 7 |
| 2013 | 3 | 7 |
| 2014 | 5 | 10 |
| 2015 | 6 | 36 |
| 2016 | 7 | 25 |
| 2017 | 12 | 22 |
| 2018 | 14 | 20 |
| 2019 | 17 | 12 |
| 2020 | 20 | 10 |
| 2021 | 4 | 13 |
| 2022 | 6 | 8 |
| 2023 | 5 | 7 |
| 2024 | 6 | 17 |
| 2025 | 1 | 6 |
| 2026 | 4 | 9 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition15 Sep 2026US 12,735,707 B2Massachusetts Eye and Ear Infirmary
- Enhancing anti-tumor response in melanoma cells with defective sting signaling14 Apr 2026US 12,599,621 B2H. Lee Moffitt Cancer Center
- KMT2A-MAML2 fusion molecules and uses thereof24 Feb 2026US 12,559,800 B2Foundation Medicine, Inc.
- Ivaltinostat combination therapy for treating pancreatic cancer17 Feb 2026US 12,553,903 B2CG Pharmaceuticals, Inc
- Method for the prognosis and treatment of cancer metastasis14 Jan 2025US 12,196,758 B2FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) and INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS
- Quantitative immunoassay for the detection of autoantibodies to nephrin1 Oct 2026US 2026/0298924 A1EUROIMMUN Medizinische Labordiagnostika AG
- Malt1 tumor inhibitor, pharmaceutical composition containing the same, and applications thereof3 Sep 2026US 2026/0258425 A1Xzyp (Beijing) Biotech Co., Ltd
- Biosignature integration to assess therapy response in breast cancer13 Aug 2026US 2026/0235605 A1Prelude Corporation
- Cardiac dilatation function improving agent, and method for screening for cardiac dilatation function improving agent6 Aug 2026US 2026/0224660 A1Keio University
- Kidney function biomarkers6 Aug 2026US 2026/0227415 A1Meso Scale Technologies, LLC.
Most cited
By later US patents
- Melanoma chemoprevention56US 9,393,225 B2University of Pittsburgh—Of the Commonwealth System of Higher Education · 2016
- Systems and methods for analyzing resource production28US 10,364,662 B1DataInfoCom USA, Inc. · 2019
- Method for the prognosis and treatment of cancer metastasis18US 9,702,878 B2Fundació Institut de Recera Biomèdica (IRB Barcelona) · 2017
- Method for detecting carcinoma16US 5,604,106 A1997
- Methods for measurement of inhibition of c-Jun N-terminal kinase in skin14US 9,513,297 B2Signal Pharmaceuticals, LLC · 2016